Acumen Pharmaceuticals, Inc. (ABOS) Misses Q2 EPS by 17c
Tweet
Share
E-mailGet Alerts ABOS Hot Sheet
Join SI Premium – FREE
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) reported Q2 EPS of ($0.68), $0.17 worse than the analyst estimate of ($0.51).
For earnings history and earnings-related data on Acumen Pharmaceuticals, Inc. (ABOS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo Upgrades Portland General Electric Company (POR) to Overweight
- Trustar Bank to acquire Forbright Bank branches for $750M in deposits
- Cantor Fitzgerald Starts Nuvation Bio Inc (NUVB) at Overweight
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
